Correspondence 0001493152-24-003480 from Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc.
Date: Jan. 23, 2024 · CIK: 0001847345 · Accession: 0001493152-24-003480
AI Filing Summary & Sentiment
File numbers found in text: 001-41293
Referenced dates: December 26, 2023
Show Raw Text
CORRESP
1
filename1.htm
Dykema
Gossett PLLC
111
E. Kilbourn Ave.
Suite
1050
Milwaukee,
WI 53202
www.dykema.com
Tel:
414-488-7300
January
23, 2024
U.S.
Securities and Exchange Commission
Division
of Corporate Finance
Office
of Real Estate & Construction
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Ameen Hamady and Kristi Marrone
Re:
PowerUp
Acquisition Corp.
Form
10-K for the year ended December 31, 2022
Filed
March 21, 2023
File
No. 001-41293
Dear
Ameen Hamady and Kristi Marrone:
This
response letter (this “Response”) is submitted on behalf of PowerUp Acquisition Corp. (the “Company”)
in response to the comments that the Company received from the staff of the Division of Corporation Finance (the “Staff”)
of the U.S. Securities and Exchange Commission (the “SEC”) in a letter dated December 26, 2023 (the “Comment
Letter”), with respect to the Company’s Form 10-K for the year ended December 31, 2022 (the “Annual Report”),
filed with the SEC on March 21, 2023.
For
reference purposes, the Staff’s numbered comment from the Comment Letter is set forth in bold text below, followed by the Company’s
response to the comment.
California
| Illinois | Michigan | Minnesota | Texas | Washington, D.C. | Wisconsin
U.S. Securities and Exchange Commission
Division of Corporate Finance
January
23, 2024
Page 2
The
response below is based on information provided to Dykema Gossett PLLC by the Company.
Form
10-K for the year ended December 31, 2022
Item
1A. Risk Factors, page 22
1.
We
note your disclosure that were you considered to be a foreign person, any proposed business combination between the Company and a
U.S. business engaged in a regulated industry or which may affect national security could be subject to foreign ownership restrictions
and/or CFIUS review which could impact your ability to complete your initial business combination. Please further expand your disclosures,
to clearly state whether your sponsor is, is controlled by, or has substantial ties with a non-U.S. person so that investors have
the necessary context to assess the risk you disclose.
Response:
The Company respectfully acknowledges the Staff’s comment and advises the Staff that the Company’s sponsor, SRIRAMA
Associates, LLC, is not currently controlled by, nor has substantial ties with non-U.S. person(s). Additionally, all officers and directors
of the Company are U.S. citizens and U.S. residents. The current owner of SRIRAMA Associates, LLC, is the Chief Executive Officer of
the Company, and to the extent additional investors are brought in to the sponsor, we are informed they will all be U.S. citizens. In
future filings with the SEC the Company, where applicable, will clarify its disclosure regarding its sponsor and whether it is, is controlled
by, or has substantial contacts with non-U.S. persons.
*
* *
Thank
you for your review and consideration of the matters set forth in this Response. If you have any questions, please contact the undersigned
at (414) 488-7321 or pwaltz@dykema.com.
Sincerely,
Dykema Gossett PLLC
By:
/s/ Peter
F. Waltz
Peter F. Waltz, Esq.
cc:
Howard
Doss
Chief
Financial Officer
PowerUp
Acquisition Corp.